arrow
R

Raffaello Ditaranto

irccs azienda ospedaliero - universitaria di bologna
H指数:11
被引数:374

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-Drug Antibodies in Patients with Fabry Disease Treated with Agalsidase-Alpha or -Beta: A Retrospective Italian Multicenter Study

法布里病患者使用阿加糖酶α或β治疗后的抗药抗体:一项意大利多中心回顾性研究

Cells
IF5.2
2026-01-010
OA
Patterns of LV Remodeling and Outcomes in Fabry Disease

LV重塑的模式及Fabry病患者的预后

2025-11-280
OAAI
Scar architecture as a structural biomarker of ventricular arrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study

瘢痕结构作为肥厚型心肌病患者室性心律失常和心源性猝死的结构生物标志物:一项心脏磁共振研究

2025-11-011
PRE
Sex-specific prognostic thresholds of left ventricular hypertrophy in fabry disease

法布雷病中左心室肥厚的性别特异性预后阈值

2025-10-010
OAAI
Electrocardiogram evolution in Anderson-Fabry disease patients during follow-up in relation to specific treatment and cardiac disease progression

安德森-法布里(Anderson-Fabry)病患者在随访期间的心电图演变,与特定治疗和心脏疾病进展的关系

2025-07-010
PRE
Arrhythmic risk stratification in patients with left ventricular ring-like scar
2024-11-011
OA
Clinical characteristics and outcome of end stage hypertrophic cardiomyopathy: Role of age and heart failure phenotypes
2024-04-013
PRE
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population

在当代肥厚型梗阻性心肌病人群中,现实世界对mavacamten的候选资格

2024-01-0211
OA
Precision Diagnosis of Hypertrophic Cardiomyopathy: A New Definition of Inappropriate Hypertrophy

肥厚型心肌病的精确诊断: 不适当肥大的新定义

2023-11-071
PRE
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure
2023-08-283
OAAI